Ong, A.C.M. orcid.org/0000-0002-7211-5400 and Gansevoort, R.T. (2021) TAMEing ADPKD with metformin : safe and effective? Kidney International, 100 (3). pp. 513-515. ISSN 0085-2538
Abstract
The biguanide metformin has been safely and widely used in the treatment of type 2 diabetes mellitus for decades. Preclinical studies have suggested that it may have a role in slowing disease progression in autosomal dominant polycystic kidney disease. In this issue, Perrone et al. report results from the Trial of Administration of Metformin in PKD (TAME PKD) study, a phase 2 randomized controlled trial investigating the safety and tolerability of metformin in patients in the early stages of autosomal dominant polycystic kidney disease. We discuss the implications of these findings and how they relate to a major phase 3 trial in autosomal dominant polycystic kidney disease that will start later in 2021.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an author produced version of a paper subsequently published in JOURNAL. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 26 Aug 2021 10:37 |
Last Modified: | 19 Aug 2022 00:13 |
Status: | Published |
Publisher: | Elsevier |
Refereed: | Yes |
Identification Number: | 10.1016/j.kint.2021.07.021 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:177480 |